Iteos Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
iTeos Therapeutics, Inc. completes merger with Concentra Biosciences, LLC, offering shareholders $10.047 cash plus a contingent value right per share.
8-K: iTeos Therapeutics to Be Acquired by Concentra Biosciences in Cash and Contingent Value Rights Deal
iTeos Therapeutics, Inc. has entered into a definitive merger agreement to be acquired by Concentra Biosciences, LLC for $10.047 per share in cash plus a contingent value right, following a unanimous board recommendation.
iTeos Therapeutics, Inc. announced that its stockholders re-elected all Class II director nominees and ratified the appointment of Deloitte Bedrijfsrevisoren / Rviseurs dEntreprises BV/SRL as its independent registered public accounting firm at the Annual Meeting held on June 17, 2025.
iTeos Therapeutics, Inc. announced the immediate resignation of Tim Van Hauwermeiren from its Board of Directors, effective June 1, 2025.
iTeos Therapeutics, Inc. announced its intention to wind down clinical and operational activities, including the termination of its belrestotug program and GSK collaboration, to maximize shareholder value through leveraging its cash balance and potential asset sales.
iTeos Therapeutics and GSK halt the development of belrestotug following unfavorable interim results from the GALAXIES Lung-201 study, prompting iTeos to initiate a strategic review to maximize shareholder value.
iTeos Therapeutics is set for a data-rich 2025 with multiple clinical readouts and the advancement of its innovative pipeline, supported by a strong cash position.
Aaron Davis, a member of the Board of Directors of iTeos Therapeutics, Inc., resigned from his position, effective November 1, 2024.
iTeos Therapeutics reported clinically meaningful objective response rates in a Phase 2 trial for its belrestotug and dostarlimab combination therapy for non-small cell lung cancer.
iTeos Therapeutics held its annual meeting on June 11, 2024, electing two Class I directors and ratifying its independent auditor.
iTeos Therapeutics has entered into agreements to raise $120 million through the sale of common stock and pre-funded warrants to RA Capital Healthcare Fund and Boxer Capital.